- Home
- KURA vs MCS Comparison
KURA vs MCS Comparison
Compare KURA & MCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KURA | MCS |
|---|---|---|
| Founded | 2014 | 1935 |
| Country | United States | United States |
| Employees | N/A | 8390 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Movies/Entertainment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 853.4M |
| IPO Year | 2015 | 1994 |
Fundamental Metrics
Financial Performance| Metric | KURA | MCS |
|---|---|---|
| Price | $10.91 | $27.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 3 |
| Target Price | ★ $25.56 | $23.33 |
| AVG Volume (30 Days) | ★ 1.8M | 170.5K |
| Earning Date | 05-12-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 1.69% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.77 |
| Revenue | $67,482,000.00 | ★ $758,458,000.00 |
| Revenue This Year | $28.28 | $12.05 |
| Revenue Next Year | $106.37 | $3.15 |
| P/E Ratio | ★ N/A | $36.10 |
| Revenue Growth | ★ 25.24 | 3.11 |
| 52 Week Low | $7.36 | $12.85 |
| 52 Week High | $13.90 | $32.42 |
Technical Indicators
Market Signals| Indicator | KURA | MCS |
|---|---|---|
| Relative Strength Index (RSI) | 41.50 | 49.09 |
| Support Level | $8.45 | $26.52 |
| Resistance Level | $11.40 | $31.15 |
| Average True Range (ATR) | 0.48 | 0.60 |
| MACD | -0.18 | -0.03 |
| Stochastic Oscillator | 6.75 | 70.52 |
Price Performance
Historical ComparisonAbout KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
About MCS Marcus Corporation (The)
Marcus Corp is engaged in two business segments, which are movie theatres and Hotels and Resorts. The movie theatres segment operates multiscreen motion picture theatres in Wisconsin, Illinois, Iowa, Minnesota, Missouri, Nebraska, North Dakota, Ohio and others, a family entertainment center in Wisconsin and a retail center in Missouri; Hotels and Resorts segment owns and operates full-service hotels and resorts in Wisconsin, Illinois, and Nebraska and manages full-service hotels, resorts and other properties in Wisconsin, Minnesota, Texas, Nevada, California, and North Carolina. It generates maximum revenue from the Theatres segment.